Payment overview · 2025
General Payments
$269.61
15 reported records · 11 companies
Healthcare provider profile · identity verified
David M Pope, MD
Allopathic & Osteopathic Physicians|Family Medicine · RICHFIELD, UT · NPI 1467554451
Verified facts
What the public records show
CMS Open Payments records show David M Pope, MD received $269.61 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.84 | 23.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.41 | 13.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.90 | 12.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.72 | 8.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.40 | 7.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.21 | 7.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.09 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.27 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.27 | 5.3% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $13.87 | 5.1% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $12.63 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $269.61 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.90 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $12.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 113 |
| Gabapentin | Gabapentin | 324 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 69 |
| Omeprazole | Omeprazole | 272 | 66 |
| Potassium Chloride | Potassium Chloride | 242 | 57 |
| Celecoxib | Celecoxib | 241 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 54 |
| Lisinopril | Lisinopril | 237 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 43 |
| Trazodone Hcl | Trazodone Hcl | 206 | 35 |
| Losartan Potassium | Losartan Potassium | 192 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 37 |
| Tramadol Hcl | Tramadol Hcl | 152 | 34 |
| Furosemide | Furosemide | 143 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 33 |
| Eliquis | Apixaban | 129 | 23 |
| Alprazolam | Alprazolam | 127 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 15 |
| Jardiance | Empagliflozin | 127 | 23 |
| Buspirone Hcl | Buspirone Hcl | 124 | 22 |
| Trulicity | Dulaglutide | 122 | 19 |
| Lorazepam | Lorazepam | 121 | 22 |
| Simvastatin | Simvastatin | 121 | 33 |
| Metformin Hcl Er | Metformin Hcl | 119 | 29 |
| Ozempic | Semaglutide | 110 | 18 |
| Allopurinol | Allopurinol | 101 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 99 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 88 | 16 |
| Prednisone | Prednisone | 87 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 19 |
| Bupropion Xl | Bupropion Hcl | 86 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 16 |
| Farxiga | Dapagliflozin Propanediol | 82 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 19 |
| Baclofen | Baclofen | 79 | 16 |
| Metformin Hcl | Metformin Hcl | 77 | 27 |
| Mirtazapine | Mirtazapine | 73 | 17 |
| Xarelto | Rivaroxaban | 72 | 12 |
| Pregabalin | Pregabalin | 66 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 51 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 60 | 12 |
| Sertraline Hcl | Sertraline Hcl | 60 | 14 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Torsemide | Torsemide | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 17 |
| Famotidine | Famotidine | 54 | 17 |
| Methocarbamol | Methocarbamol | 54 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 16 |
| Finasteride | Finasteride | 49 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Belsomra | Suvorexant | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | 12 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 13 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 14 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 41 | 41 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 40 | 12 |
| Zaleplon | Zaleplon | 40 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 38 | 38 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 11 |
| Primidone | Primidone | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Acetylcysteine | Acetylcysteine | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | 11 |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Colchicine | Colchicine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $269.61 · 15 records | ABBVIE INC. | BEYFORTUS, CAPLYTA, CAPVAXIVE, ENFLONSIA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, Korlym, NEXPLANON, Ozempic, Physio-Stim, SUBLOCADE, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error